The enhanced renin-angiotensin-aldosteron system pharmacological blockade - Which is the best?

Kidney and Blood Pressure Research

Volumn 36, Issue 1, 2012, Pages 335-343

  Tylicki, Leszek ^a   Slawomir Lizakowski ^a   Przemyslaw Rutkowski ^a   Renke, Marcin ^a   Sulikowska, Beata ^b   Heleniak, Zbigniew ^a   Donderski, Rafał ^b   Bednarski, Rafał ^b   Przybylska, Milena ^a   Manitius, Jacek ^b   Rutkowski, Bolesław ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Angiotensin II receptor antagonist; Chronic kidney disease; Mineralocorticoid receptor antagonist; Proteinuria; Renin angiotensin aldosteron system; Renin inhibitor

Indexed keywords

ALBUMIN; ALISKIREN; CREATININE; EPLERENONE; PERINDOPRIL; TELMISARTAN;

ADULT; ALBUMINURIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; MALE; MONOTHERAPY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADULT; ALBUMINURIA; AMIDES; ANGIOTENSIN RECEPTOR ANTAGONISTS; BENZIMIDAZOLES; BENZOATES; COMORBIDITY; CROSS-OVER STUDIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FUMARATES; HUMANS; HYPERTENSION; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PROSPECTIVE STUDIES; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; RENIN; RENIN-ANGIOTENSIN SYSTEM; SEVERITY OF ILLNESS INDEX; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84870757645     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000343391     Document Type: Article

References (35)

1. Nakamura T, Fujiwara N, Sato E, Ueda Y, Sugaya T, Koide H: Renoprotective effects of various angiotensin II receptor blockers in patients with early-stage diabetic nephropathy. Kidney Blood Press Res 2010;33:213-220.
2. Tylicki L, Larczynski W, Rutkowski B: Renal protective effects of the renin-angiotensin-aldosterone system blockade: From evidence-based approach to perspectives. Kidney Blood Press Res 2005;28:230-242.
3. Siamopoulos KC, Kalaitzidis RG: Inhibition of the renin-angiotensin system and chronic kidney disease. Int Urol Nephrol 2008;40:1015-1025.
4. The Gisen group (Gruppo Italiano Di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effects of ramipril on decline in glomerular filatration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-1863.
5. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group. N Engl J Med 1996;334:939-945.
6. Tylicki L, Rutkowski P, Renke M, Rutkowski B: Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Am J Nephrol 2002;22:356-362.
7. Bianchi S, Bigazzi R, Campese VM: Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study. Am J Kidney Dis 2005;36:45-51.
8. Lizakowski S, Tylicki L, Renke M, Rutkowski P, Heleniak Z, Slawinska Morawska M, Aleksandrowicz Wrona E, Lysiak-Szydlowska W, Rutkowski B: The effect of aliskiren on proteinuria in chronic nondiabetic kidney disease: A double-blind cross-over randomised controlled trial. Int Urol Nephrol 2012; in press.
9. Shiigai T, Shichiri M: Late escape from the antiproteinuric effect of ACE inhibitors in nodiabetic disease. Am J Kidney Dis 2001;2001:477-483.
10. Tylicki L, Lizakowski S, Rutkowski B: Renin-angiotensin-aldosterone system blockade for nephroprotection: Current evidence and future directions. J Nephrol 2012;25:900-910.
11. Maroni BJ, Steinman TI, Mitch WE: A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 1985;27:58-65.
12. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
13. Gansevoort R, De Zeeuw D, De Jong P: Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system ? Kidney Int 1994;45:861-867.
14. Ruggenenti P, Perna A, Gheradi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena F, Remuzzi G: Renoprtective properties of ace-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354:359-364.
15. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (Gisen). Ramipril efficacy in nephropathy. Lancet 1998;352:1252-1256.
16. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER, 3rd, Norris K, O'Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT, Jr., Xu S: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 2001;285:2719-2728.
17. Tylicki L, Renke M, Rutkowski P, Rutkowski B, Lysiak-Szydlowska W: Randomized, controlled study of the effects of losartan versus enalapril in small doses on proteinuria and tubular injury in primary glomerulonephritis. Med Sci Monit 2005;11:PI31-PI37.
18. Forclaz A, Maillard M, Nussberger J, Brunner HR, Burnier M: Angiotensin II receptor blockade: Is there truly a benefit of adding an ACE inhibitor? Hypertension 2003;41:31-36.
19. Campbel R, Sangalli F, Perticuccu E, Aros C, Viscarra C, Perna A, Remuzzi A, Bertocchi F, Fagiani L, Remuzzi G, Ruggenenti P: Effects of combined ace inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003;63:1094-1103.
20. Laverman G, Navis G, Henning R, De Jong P, De Zeeuw D: Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002;62:1020-1025.
21. Russo D, Pisani A, Balletta M, De Nicola L, Savino F, Andreucci M, Minutolo R: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999;33:851-856.
22. Rutkowski P, Tylicki L, Renke M, Korejwo G, Zdrojewski Z, Rutkowski B: Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am J Kidney Dis 2004;43:260-268.
23. Chrysostomou A, Becker G: Spironolactone in addition to ace inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001;345:925-926.
24. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-LEFT ventricular hypertrophy study. Circulation 2003;108:1831-1838.
25. Tylicki L, Rutkowski P, Renke M, Larczynski W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B: Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: An open-label crossover randomized controlled trial. Am J Kidney Dis 2008;52:486-493.
26. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-2446.
27. Aranda P, Segura J, Ruilope LM, Aranda FJ, Frutos MA, Lopez V, Lopez de Novales E: Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis 2005;46:1074-1079.
28. Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C: Additional antiproteinuric effect of ultrahigh dose candesartan: A double-blind, randomized, prospective study. J Am Soc Nephrol 2005;16:3038-3045.
29. Adamczak M, Gross M, Krtil J, Koch A, Tyralla K, Amann K, Ritz E: Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J Am Soc Nephrol 2003;14:2833-2842.
30. Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB: Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 2005;16:3306-3314.
31. Ma LJ, Nakamura S, Aldigier JC, Rossini M, Yang H, Liang X, Nakamura I, Marcantoni C, Fogo AB: Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol 2005;16:966-976.
32. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA: Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med DOI: 10.1056/NEJMoa1208799.
33. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (The ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-553.
34. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF: Aldosterone antagonists for preventing the progression of chronic kidney disease: A systematic review and meta-analysis. Clin J Am Soc Nephrol 2009;4:542-551.
35. Toto RD: RAS blockade, hyperkalemia and AKI-look and you will find. Nat Rev Nephrol 2012;8:257-258.